Pharmacogenetic Predictors of Methylphenidate Dose-Response in Attention-Deficit/Hyperactivity Disorder

This publication has 75 references indexed in Scilit:

• Progress and Promise of Attention-Deficit Hyperactivity Disorder Pharmacogenetics
  CNS Drugs, 2010
• A Candidate Gene Analysis of Methylphenidate Response in Attention-Deficit/Hyperactivity Disorder
  Journal of the American Academy of Child & Adolescent Psychiatry, 2009
• Genome‐wide association study of response to methylphenidate in 187 children with attention‐deficit/hyperactivity disorder
  American Journal Of Medical Genetics Part B-Neuropsychiatric Genetics, 2008
• The impact of individual and methodological factors in the variability of response to methylphenidate in ADHD pharmacogenetic studies from four different continents
  American Journal Of Medical Genetics Part B-Neuropsychiatric Genetics, 2008
• Pharmacogenetics of methylphenidate response in attention deficit/hyperactivity disorder: Association with the dopamine transporter gene (SLC6A3)
  American Journal Of Medical Genetics Part B-Neuropsychiatric Genetics, 2008
• The Pharmacogenomic Era: Promise for Personalizing Attention Deficit Hyperactivity Disorder Therapy
  Child and Adolescent Psychiatric Clinics of North America, 2008
• Prevalence, Recognition, and Treatment of Attention-Deficit/Hyperactivity Disorder in a National Sample of US Children
  Archives of Pediatrics & Adolescent Medicine, 2007
• No significant association between response to methylphenidate and genes of the dopaminergic and serotonergic systems in a sample of Brazilian children with attention‐deficit/hyperactivity disorder
  American Journal Of Medical Genetics Part B-Neuropsychiatric Genetics, 2006
• Dopamine transporter genotype influences the physiological response to medication in ADHD
  Brain, 2006
• Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders
  Pharmacogenetics, 1996